Research Article

Experimental Autoimmune Encephalomyelitis Development Is Aggravated by Candida albicans Infection

Thais F. C. Fraga-Silva,1 Luiza A. N. Mimura,1 Camila M. Marchetti,2 Fernanda Chiuso-Minicucci,1 Thais G. D. França,1 Sofia F. G. Zorzella-Pezavento,1 James Venturini,2 Maria S. P. Arruda,2 and Alexandrina Sartori1

1Department of Microbiology and Immunology, Biosciences Institute, São Paulo State University (UNESP), 18618-000 Botucatu, SP, Brazil
2Department of Biological Sciences, School of Sciences, São Paulo State University (UNESP), 17033-360 Bauru, SP, Brazil

Correspondence should be addressed to Alexandrina Sartori; sartori@ibb.unesp.br

Received 18 September 2014; Revised 19 January 2015; Accepted 22 January 2015

Academic Editor: Oscar Bottasso

Multiple sclerosis (MS) is an inflammatory/autoimmune and demyelinating disease of the central nervous system (CNS) mainly mediated by myelin specific T cells. It is widely believed that environmental factors, including fungal infections, contribute to disease induction or evolution. Even though Candida infection among MS patients has been described, the participation of this fungus in this pathology is not clear. The purpose of this work was to evaluate the effect of a Candida albicans infection on experimental autoimmune encephalomyelitis (EAE) that is a widely accepted model to study MS. Female C57BL/6 mice were infected with C. albicans and 3 days later, animals were submitted to EAE induction by immunization with myelin oligodendrocyte glycoprotein. Previous infection increased the clinical score and also the body weight loss. EAE aggravation was associated with expansion of peripheral CD4+ T cells and production of high levels of TNF-α, IFN-γ IL-6, and IL-17 by spleen and CNS cells. In addition to yeast and hyphae, fungus specific T cells were found in the CNS. These findings suggest that C. albicans infection before EAE induction aggravates EAE, and possibly MS, mainly by CNS dissemination and local induction of encephalitogenic cytokines. Peripheral production of encephalitogenic cytokines could also contribute to disease aggravation.

1. Introduction

Multiple sclerosis (MS) is an inflammatory/autoimmune and demyelinating disease of the central nervous system (CNS). It is considered one of the most common neurological disorders and causes of disability in young adults [1]. The estimated number of people with MS has increased from 2.1 million in 2008 to 2.3 million in 2013 [2]. Animal models, particularly experimental autoimmune encephalomyelitis (EAE), have been essential to decipher the pathophysiology of MS [3–6]. MS and EAE are characterized by an autoimmune response against CNS proteins, mediated mainly by T cells, that culminates in inflammatory infiltrate, gliosis, damage of myelin sheath, and neuronal death [7–9].

This disease is thought to be triggered by a complex interaction between genetic and environmental factors. Expressive data confirm that genetic variation is an important determinant for MS risk. Population, family, and molecular studies strongly support a polygenic model of inheritance, driven primarily by allelic variants relatively common in the general population. The major histocompatibility complex is believed to be the strongest MS susceptibility locus genome-wide and was identified in all studied populations [10]. It has also long been recognized that infections may serve as environmental triggers for this disease. A large number of pathogens, including worldwide distributed fungi, have been proposed to be associated with MS [11]. As most of the systemic fungal pathogens have been associated with
dissemination to the CNS [12], they could contribute to local tissue destruction by their presence or, alternatively, by the induction of a local immune response.

Candida spp. is one of these pathogens that could contribute to MS development. C. albicans is a pleomorphic fungus that colonizes the majority of healthy human individuals. This fungus can behave as a normal component of the microbiota and also as an opportunistic pathogen that causes superficial mucosal infections as well as disseminated disease [13, 14]. As the fourth most common cause of nosocomial infections, C. albicans is commonly isolated from immunocompromised individuals, including those with HIV, those immunosuppressed due to cancer treatment, and premature babies [15]. A possible association between MS and Candida spp. has been suggested by serological evidences. A significantly higher level of Candida specific antibodies was detected in MS patients than in normal control individuals [16]. In addition, Candida spp. antigens were also demonstrated in the cerebrospinal fluid of some MS patients [17].

The possible contribution of Candida spp. to MS pathogenesis was initially attributed to cross-reactivity with human tissues, including brain structures [18]. More recently, it was proposed that Candida, sequestered in nonneuronal tissues, could release toxins that would destroy astrocytes and oligodendrocytes generating myelin debris that would then trigger a pathogenic immune response in the CNS [19]. Furthermore, the presence of yeast and hyphae in the brain recruits inflammatory cells and elicits expansion of microglia cells [20]. Considering that the possible contribution of C. albicans to MS needs to be investigated and that elucidation of this could affect the treatment of this disease, we evaluated the possible deleterious effect of a previous C. albicans infection on EAE development.

2. Methods

2.1. Animals. Female C57BL/6 mice 9–11 weeks old were purchased from University of São Paulo (USP) (Ribeirão Preto, SP, Brazil). The animals received sterilized food and water ad libitum and were manipulated in accordance with the local Ethics Committee for Animal Experimentation (CEEA), São Paulo State University (UNESP) (Botucatu, SP, Brazil; protocol number 35).

2.2. EAE Induction. MOG35–55 peptide (MEVGWYRSPFSRVVHYLRNGK) was synthesized by Genemed Synthesis Inc. (San Antonio, Texas, USA). Mice were immunized subcutaneously with 100 μg of MOG35–55 peptide emulsified in 25 μL of Complete Freund’s Adjuvant (CFA) containing 4 mg/mL of Mycobacterium tuberculosis. Mice also received 2 intraperitoneal doses, 0 and 48 hours after immunization, of 200 ng of Bordetella pertussis toxin (Sigma-Aldrich Corporation, St. Louis, MO, USA). EAE clinical assessment was daily performed according to the following criteria: 0, no symptoms; 1, limp tail; 2, hind legs weakness; 3, partially paralyzed hind legs; 4, complete hind leg paralysis; and 5, complete paralysis/death. The % of weight loss and the maximum clinical score were calculated considering the highest body weight loss and the highest clinical score that each animal reached during the experiment, independently of the period, and the result was expressed as the mean per experimental group.

2.3. Fungi. C. albicans strain FCF 14 (Genbank Accession EF591020) was originally obtained from the mycology collection of the Faculdade de Odontologia de São José dos Campos, UNESP, and maintained in our mycological collection on Sabouraud-dextrose agar (Difco Laboratories, Detroit, MI, USA). For mice infection, C. albicans was cultured on solid media during 24 hours at 37°C. The fungal concentration was adjusted to 5.0 × 10⁷/mL viable yeast cells in sterile saline solution (SSS). Fungus suspension was then inoculated into the lateral tail vein (0.1 mL/animal).

2.4. Fungal Load Determination. Samples from spleen, kidney, liver, brain, and spinal cord were weighted and macerated in 1.0 mL of SSS. Afterwards, 0.1 mL from each tissue homogenate was spread over culture plates containing Sabouraud-dextrose agar using a Drigalski T loop. The procedures were performed in duplicate. The plates were then sealed and incubated at 37°C for 3 days. The number of colony forming units (CFU) was normalized per gram of tissue.

2.5. CNS-Mononuclear Cells Isolation. Fourteen days after EAE induction, mice were anesthetized with ketamine/xylazine and perfused with 10 mL of SSS. Brain and spinal cord were collected, macerated, and digested with 2.5 mg/mL of collagenase D (Roche Applied Science, Indianapolis, IN, USA) in 4 mL of RPMI (Sigma) at 37°C for 45 min. Then, suspensions were washed in RPMI and centrifuged at 450 × g at 4°C for 15 min. Cells were resuspended in Percoll (Sigma) 37% and gently laid over Percoll 70% in tubes of 15 mL. The tubes were centrifuged at 950 × g for 20 min with centrifuge breaks turned off. After centrifugation the ring containing mononuclear cells was collected, washed in RPMI, and centrifuged at 450 × g for 10 min. Cells were then resuspended in complete RPMI medium (RPMI supplemented with 10% of fetal bovine serum), counted, and analyzed.

2.6. Cell Culture Conditions and Cytokine Quantification. Spleen and CNS-isolated cells were collected and adjusted to 5 × 10⁶ cells/mL and 2 × 10⁵ cells/mL, respectively, in complete RPMI medium. Spleen and CNS-isolated cells were plated and stimulated with MOG (20 μg/mL and 50 μg/mL, resp.) and with C. albicans (5 yeasts/1 cell). Cytokine levels were evaluated 48 h later by enzyme-linked immunosorbent assay (ELISA) in culture supernatants using IFN-γ and IL-2, IL-4, IL-6, IL-10, IL-17, and TNF-α Duosets (R&D Systems, Minneapolis, MN, USA). The assays were performed according to the manufacturer’s instructions.

2.7. FACS Analysis. Spleen cells were collected; the red blood cells were lysed with buffer containing NH₄Cl, and adjusted to 10⁶ cells/tube. CNS-extracted cells were plated at 5 × 10⁵ cells/well and stimulated with MOG (125 μg/mL) and with C. albicans (5 yeasts/1 cell). After incubation at 37°C for
48 h, cells were collected and stained. Spleen and CNS-extracted cells were blocked with rat serum 1% for 20 min to prevent nonspecific binding via Fc receptor. After Fc blocking, cells were stained with $0.2 \mu g$ of PerCP-conjugated anti-mouse CD3 and $0.25 \mu g$ of FITC-conjugated anti-mouse CD4 for 20 min at 4°C. Intracellular FoxP3 transcription factor analysis was performed only in spleen samples by using CD3-PercP, CD4-FITC plus $0.13 \mu g$ of APC-conjugated anti-mouse CD25 and $0.2 \mu g$ of PE-conjugated anti-mouse FoxP3 and staining set (eBiosciences, San Diego, CA, USA) according to manufacturer’s instructions. After staining, the cells were washed, resuspended in FACS buffer, and fixed in paraformaldehyde 1%. Analysis was performed using a FACS Canto II (BD) from Bioscience Institute (Botucatu, SP, Brazil) and the data were analyzed with FlowJo software (TreeStar, Ashland, OR, USA).

2.8. Histopathology of the CNS. After euthanasia, brain and lumbar spinal cord samples were removed and fixed in 10% neutral buffered formalin. Paraffin slides with $4 \mu m$ were stained with hematoxylin and eosin (H&E) to evaluate the inflammatory process. A semiquantitative analysis of CNS inflammation was performed according to the following criteria: (0) inflammatory infiltration absent; (+/++) mild/moderate inflammatory infiltration; (+++) intense inflammatory infiltration. Sections were also stained with periodic acid-Schiff to visualize fungal structures.

2.9. Statistical Analysis. Results were expressed as mean ± standard deviation or with median and interquartile (25–75%) ranges. To test for the normality of data, results were analyzed by Shapiro-Wilk’s test. Comparisons between two samples were made by $t$-test and more than three samples were made by one way ANOVA followed by Tukey’s test for parametric variables and by Kruskal-Wallis followed by Dunn’s test for nonparametric variables. Fisher’s test was performed to estimate the frequency of \textit{C. albicans}-positive tissues and to compare the semiquantitative analysis of CNS tissue inflammation. The data were analyzed using SigmaPlot statistical package for Windows version 2.0 (1995, Jandel Corporation, CA, USA) and values of $P < 0.05$ were considered statistically significant.

3. Results

3.1. \textit{Candida albicans} Infection Disseminates to the CNS. We initially tested the characteristics of the \textit{C. albicans} infection in C57BL/6 mice as this is one of the strains that are susceptible to EAE induction. Experimental infection with \textit{C. albicans} in C57BL/6 mice determined a disseminated infection that
also reached the CNS. As observed in Table 1, the viable fungi were recovered from all evaluated organs, including the brain and the spinal cord. After 30 days all organs, except the spleen, exhibited fungal clearance. The kinetics of fungal load, during 30 days, is showed in Figures 1(a) and 1(b) for brain and spinal cord, respectively, and indicates that the fungus load is more accentuated in the first week of infection. The presence of yeasts and hyphae in the brain and yeast in the spinal cord is illustrated in Figures 1(c) and 1(d), respectively.

3.2. Production of Potentially Encephalitogenic Cytokines during C. albicans Infection. As many of the most encephalitogenic cytokines are also involved in the defense against C. albicans and other fungi, we tested their production during the time periods when the fungus was being detected. Spleen cell cultures from infected mice produced elevated levels of TNF-α, IL-6, IFN-γ, and IL-17 (Figure 2). Cytokine levels were especially elevated in the 3rd day after infection.

Table 1: Frequency of C. albicans-positive tissues.

| Period | Spleen | Kidney | Liver | Brain | Spinal cord |
|--------|--------|--------|-------|-------|-------------|
| 3 days | 6/6    | 6/6    | 5/6   | 5/6   | 5/6         |
| 7 days | 5/5    | 5/5    | 3/5   | 5/5   | 3/5         |
| 14 days| 4/6    | 2/6    | 0/6   | 4/6   | 1/6         |
| 21 days| 4/6    | 1/6    | 0/6   | 2/6   | 1/6         |
| 30 days| 2/5    | 0/6    | 0/6   | 0/6   | 0/5         |

Data were expressed as number of C. albicans-positive animals/total number of animals per group.

3.3. Infection with C. albicans Aggravates EAE Development. To test the possible deleterious role of C. albicans on EAE development, EAE was induced in mice that had been infected three days before with the fungus. Mice previously infected, denominated EAE+Ca group, developed a more
severe form of encephalomyelitis. As shown in Figure 3(a),
these animals already showed paralysis signs at the 9th day
after EAE induction whereas the EAE control group pre-
sented paralysis only 2 days later. This higher disease severity
was detected during the whole acute disease phase. The
average maximum clinical score, as depicted in Figure 3(b),
confirmed this worst clinical evolution. Weight loss was
also more accentuated in this experimental group as can be
observed in Figure 3(c).

3.4. Peripheral Immunological Alterations during EAE Aggra-
vation by C. albicans Infection. To evaluate if peripheral
immunological parameters could explain this detrimental
fungal effect on EAE, we tested the % of CD3⁺CD4⁺ and
CD3⁺CD4⁺CD25⁺FoxP3⁺ T-cell subsets. The cytokine pro-
duction by spleen cells restimulated with MOG or with
heat-killed C. albicans yeasts was also determined. Normal
mice and mice only infected were also analyzed. A higher percentage of CD3⁺CD4⁺ T cells were found in EAE+Ca and
EAE groups in comparison to normal and infected groups. In
addition, the % of this T-cell subset was significantly higher
in the group that was previously infected with the fungus
(EAE+Ca) in comparison to the EAE group (Figure 4(a)).
The % of the FoxP3⁺ T cells was significantly higher in
the EAE, but not in the Ca and EAE+Ca groups, in com-
parison to the control group, as illustrated in Figure 4(b).
Concerning cytokines induced by MOG, the EAE+Ca group
presented a significant production of TNF-α (Figure 4(d)),
IL-6 (Figure 4(e)), and IL-17 (Figure 4(f)) in comparison to
all other experimental groups. IL-2 (Figure 4(h)) and IL-4
(Figure 4(i)) were similarly elevated in EAE and EAE+Ca
groups. These two groups also produced low and similar
amounts of IL-10 (Figure 4(c)). Comparison of EAE+Ca and
EAE cytokine production induced by heat-killed C. albicans
clearly showed that IL-10, IL-6, IL-17, IFN-γ, IL-2, and IL-4
were significantly higher in the previously infected group.

3.5. Local Immunological Alterations during EAE Aggravation
by C. albicans Infection. H&E staining clearly indicated a
strong and similar inflammatory process in the brain and
spinal cord of both EAE and EAE+Ca animals, as shown
in Figure 5. This analogous inflammatory process was con-
firmation by a semiquantitative analysis done in both brain
and spinal cord samples (data not shown). As expected,
Figure 4: Continued.
Figure 4: Modulation of MOG-induced cytokine production by previous infection with C. albicans. C57BL/6 mice were infected with C. albicans and 3 days later they were submitted to EAE induction. Fourteen days after EAE induction, some immunological parameters were evaluated in the spleen. The percentage of CD3^+ CD4^+ (a) and CD3^+ CD4^+ CD25^+ FoxP3^+ (b) was performed by cytometric analysis in 100,000 acquired events. IL-10 (c), TNF-α (d), IL-6 (e), IL-17 (f), IFN-γ (g), IL-2 (h), and IL-4 (i) levels were measured in spleen cell cultures stimulated with MOG or heat-killed C. albicans. The results are expressed as mean ± SD (n = 6–8 mice/group). ANOVA, Tukey’s test, and P < 0.05. Different letters indicate statistical difference among the groups (a and b) or among the groups under the same in vitro stimulation (c, d, e, f, g, h, and i).
Figure 5: Previous infection with C. albicans increases the amount of CD4$^+$ T cells in the CNS. C57BL/6 mice were infected with C. albicans and 3 days later they were submitted to EAE induction. Fourteen days after EAE induction, inflammation and % of CD4$^+$ T cells were evaluated in the CNS. Inflammatory infiltrates detected by H&E staining are shown in brain samples from EAE (b) and from EAE+Ca (c) groups and in spinal cord samples from EAE (e) and from EAE+Ca (f) groups. A brain and spinal cord samples from a normal mouse is shown in (a) and (d), respectively. Total leukocyte number (g) and percentage of CD3$^+$ CD4$^+$ T-cell subset (h) (analysis performed in 50,000 acquired events). The results are expressed as mean ± SD (n = 6-7 mice/group). Unpaired t test, $^*$ P < 0.05 and $^{**}$ P < 0.01 indicate difference between EAE and EAE+Ca groups under the same in vitro stimulation.

In addition, developed a more severe disease. Higher severity was characterized by both a higher body weight loss and a more accentuated degree of paralysis. To the best of our knowledge, this is the first demonstration that a previous experimental infection with C. albicans triggered EAE exacerbation. These findings are relevant because a direct contribution of C. albicans to this neurological disease has not been deeply investigated. However, a series of indirect and epidemiological findings supports this possibility. For example, Purzycki and Shain [19] proposed that certain pathogenic fungi could release toxins that, by destroying CNS astrocytes and oligodendrocytes, would degrade myelin triggering the onset of MS and its associated symptoms. By using immunofluorescence analysis, Benito-León et al. [16] suggested a serological evidence of a link between Candida infection and MS condition. By comparing the amount of anti-Candida antibodies in the sera of normal subjects and MS patients, these authors suggested that infections with
Figure 6: Candida specific T cells contribute to elevated production of encephalitogenic cytokines in the CNS. CNS eluted cells were restimulated with MOG or heat-killed C. albicans and TNF-α (a), IL-6 (b), IL-17 (c), IFN-γ (d), IL-2 (e), and IL-10 (f) levels were measured by ELISA. The results are expressed as median, 25–75% (box), and minimum-maximum (error bars) of 6 to 7 mice/group. Mann-Whitney test, *P < 0.05 and **P < 0.01 indicate statistical difference between EAE and EAE+Ca groups under the same in vitro stimulation.

Candida spp. could be associated with increased odds of MS [16]. In addition to specific antibodies, fungal macromolecules such as proteins, polysaccharides, and DNA were also detected in blood samples from MS patients [33]. Besides these serologic evidences, antibodies against Candida spp. [33] and fungal DNA [17] were also detected in the cerebrospinal fluid of MS patients.

To unravel, at least partially, the immunological mechanism involved in this effect, some peripheral immunological parameters were compared among EAE, EAE+Ca,
C. albicans infected (Ca), and normal (CTL) experimental groups. Even though T regulatory (Treg) mediated responses remain poorly understood in Candida infection, data indicate increased proportion of this subset during candidiasis [34, 35]. As FoxP3+ T cells are mostly responsible for EAE recovery in C57BL/6 mice [36, 37], we initially hypothesized that Treg expansion could theoretically downregulate EAE development. This assumption was based on the fact that Treg cells induced during infectious diseases can regulate EAE in an apparently nonspecific manner [38]. To test this possibility we evaluated the effect of the C. albicans infection on the percentage of this T-cell subset. The expected increase in the percentage of FoxP3+ T cells was found in the spleen of the EAE group. However, the proportion of this T-cell subset was not modified in Ca and in EAE+Ca groups. This finding can be attributed, at least partially, to the complex relationship, including cell plasticity, between Treg and Th17 responses during C. albicans infection [35]. In addition to Treg cells we also evaluated the percentage of CD4+ T cells and cytokine production. Previous fungal infection increased CD4+ T-cell subset in spleen of EAE-mice (EAE+Ca group) and clearly upmodulated the production of many encephalitogenic cytokines by spleen cells stimulated with MOG or heat-killed C. albicans. Even though the effect of EAE on fungal load was not the focus of this investigation, fungi recovery was usually significantly lower in the infected animals that had also EAE (not shown). This finding suggests that the immune response against MOG, or maybe the presence of the CFA, is increasing fungicidal activity of the immune system. The higher production of encephalitogenic cytokines by both stimuli, MOG and C. albicans, was interpreted as a possible cause of EAE increased severity as cytokines can easily cross the blood-brain barrier and directly affect CNS functions [39, 40].

As the histopathology analysis from brain and spinal cord sections suggested similar degrees of inflammation, we compared the amounts of leukocytes and CD3+ CD4+ T cells eluted from the CNS. Confirming the H&E analysis, this comparison revealed the presence of similar numbers of total cells in EAE and EAE+Ca groups, demonstrating therefore that the higher disease severity was not due to a higher degree of inflammatory infiltration. Nevertheless, the immunophenotyping analysis showed a higher proportion of CD3+ CD4+ T-cell population in the EAE+Ca group. Culture of the cells eluted from the CNS showed, as expected, that they produced proinflammatory cytokines in the presence of MOG. Interestingly, they also produced significant amounts of proinflammatory cytokines when stimulated with C. albicans.

Together, these results are suggesting that both peripheral and local fungus effects are contributing to a more severe disease development. The translation of these findings to human patients certainly requires much more investigation in this area. However, we believe that these findings add more evidence that C. albicans is one of the fungi that can affect this type of neurological pathology.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**Acknowledgment**

Special thanks are due to São Paulo Research Foundation (FAPESP), Grant no. 2013/14353-2 and Grant no. 2012/12540-7.

**References**

[1] R. Hohlfeld, “Multiple sclerosis: human model for EAE?” *European Journal of Immunology*, vol. 39, no. 8, pp. 2036–2039, 2009.

[2] Multiple Sclerosis International Federation—MSIF, *The Atlas of Multiple Sclerosis 2013*, Multiple Sclerosis International Federation, London, UK, 2013.

[3] E. Lavi and C. S. Constantinescu, *Experimental Models of Multiple Sclerosis*, Springer, New York, NY, USA, 2005.

[4] M. Sospedra and R. Martin, “Immunology of multiple sclerosis,” *Annual Review of Immunology*, vol. 23, pp. 683–747, 2005.

[5] A. G. Baxter, “The origin and application of experimental autoimmune encephalomyelitis,” *Nature Reviews Immunology*, vol. 7, no. 11, pp. 904–912, 2007.

[6] C. Cassan and R. S. Liblau, “Immune tolerance and control of CNS autoimmunity: from animal models to MS patients,” *Journal of Neurochemistry*, vol. 100, no. 4, pp. 883–892, 2007.

[7] H. Neumann, “Molecular mechanisms of axonal damage in inflammatory central nervous system diseases,” *Current Opinion in Neurology*, vol. 16, no. 3, pp. 267–273, 2003.

[8] N. M. Rebenko-Moll, L. Liu, A. Cardona, and R. M. Ransohoff, “Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details,” *Current Opinion in Immunology*, vol. 18, no. 6, pp. 683–689, 2006.

[9] M. Rodriguez, “Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis,” *Brain Pathology*, vol. 17, no. 2, pp. 219–229, 2007.

[10] J. R. Oksenberg, “Decoding multiple sclerosis: an update on genomics and future directions,” *Expert Review of Neurotherapeutics*, vol. 13, no. 12, pp. 11–19, 2013.

[11] A. Venkatesan and R. T. Johnson, “Infections and multiple sclerosis,” *Handbook of Clinical Neurology*, vol. 122, pp. 151–171, 2014.

[12] J. M. K. Murthy and C. Sundaram, “Fungal infections of the central nervous system,” *Handbook of Clinical Neurology*, vol. 121, pp. 1383–1401, 2014.

[13] S. K. Fridkin and W. R. Jarvis, “Epidemiology of nosocomial fungal infections,” *Clinical Microbiology Reviews*, vol. 9, no. 4, pp. 499–511, 1996.

[14] F. L. van de Veerdonk, M. G. Netea, L. A. Joosten, J. W. M. van der Meer, and B. J. Kullberg, “Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy,” *FEMS Microbiology Reviews*, vol. 34, no. 6, pp. 1063–1075, 2010.

[15] H. Wispelinghoff, T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond, “Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study,” *Clinical Infectious Diseases*, vol. 39, p. 309, 2004.

[16] J. Benito-León, D. Pisa, R. Alonso, P. Calleja, M. Díaz-Sánchez, and L. Carrasco, “Association between multiple sclerosis and Candida species: evidence from a case-control study,” *European Journal of Clinical Microbiology & Infectious Diseases*, vol. 29, no. 9, pp. 1139–1145, 2010.
D. Pisa, R. Alonso, F. J. Jiménez-Jiménez, and L. Carrasco, “Fungal infection in cerebrospinal fluid from some patients with multiple sclerosis,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 36, no. 6, pp. 795–801, 2013.

A. Vojdani, P. Rahimian, H. Kalhor, and E. Mordechai, “Immunological cross reactivity between Candida albicans and human tissue,” Journal of clinical & laboratory immunology, vol. 48, no. 1, pp. 1–15, 1996.

C. B. Purzycki and D. H. Shain, “Fungal toxins and multiple sclerosis: a compelling connection,” Brain Research Bulletin, vol. 82, no. 1-2, pp. 4–6, 2010.

M. S. Lionakis, J. K. Lim, C.-C. R. Lee, and P. M. Murphy, “Organ-specific innate immune responses in a mouse model of invasive candidiasis,” Journal of Innate Immunity, vol. 3, no. 2, pp. 180–199, 2011.

P. A. Davis and P. T. Rudd, Neonatal Meningitis, McKeith Press, London, UK, 1994.

D. H. Del Brutto, “Central nervous mycotic infections,” Revue Neurologique, vol. 30, pp. 447–459, 2000.

J. Sánchez-Portocarrero, E. Pérez-Cecilia, O. Corral, J. Romero-Vivas, and J. J. Picazo, “The central nervous system and infection by Candida species,” Diagnostic Microbiology and Infectious Disease, vol. 37, no. 3, pp. 169–179, 2000.

A. Borha, I.-J. Parienti, E. Emery, O. Coskun, S. Khouri, and J.-M. Derlon, “Candida Albicans cerebral granuloma in an immunocompetent patient. A case report,” Neurochirurgie, vol. 55, no. 1, pp. 57–62, 2009.

A. Ben-Nun, N. Kaushansky, N. Kawakami et al., “From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development,” Journal of Autoimmunity, vol. 54, pp. 33–50, 2014.

C. C. A. Bernard, T. G. Johns, A. Slavin et al., “Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis,” Journal of Molecular Medicine, vol. 75, no. 2, pp. 77–88, 1997.

D. H. M. L. P. Navarathna, J. Munasinghe, M. J. Lizak, D. Nayak, D. B. Mc Gavin, and D. D. Roberts, “MRI confirms loss of blood-brain barrier integrity in a mouse model of disseminated candidiasis,” NMR in Biomedicine, vol. 26, no. 9, pp. 1125–1134, 2013.

T. F. C. Fraga-Silva, J. Venturini, and M. S. P. de Arruda, “Trafficfing of phagocytic peritoneal cells in hypoinsulinemic-hyperglycemic mice with systemic candidiasis,” BMC Infectious Diseases, vol. 13, article 147, 2013.

W. E. F. Klinkert, K. Kojima, W. Lesslauer, W. Rinner, H. Lassmann, and H. Wekerle, “TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview,” Journal of Neuroimmunolology, vol. 72, no. 2, pp. 163–168, 1997.

C. Lock, G. Hermans, R. Pedotti et al., “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis,” Nature Medicine, vol. 8, no. 5, pp. 500–508, 2002.

J. M. Fletcher, S. J. Lalor, C. M. Sweeney, N. Tubridy, and K. H. G. Mills, “T cells in multiple sclerosis and experimental autoimmune encephalomyelitis,” Clinical and Experimental Immunology, vol. 162, no. 1, pp. 1–11, 2010.

D. W. Luchtman, E. Ellwardt, C. Larochelle, and F. Zipp, “IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments,” Cytokine & Growth Factor Reviews, vol. 25, no. 4, pp. 403–413, 2014.